ADRX
ADRX clinical trials: ADARx Pharmaceuticals, Inc.
Every trial on ClinicalTrials.gov where ADARx Pharmaceuticals, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 9
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
ADRX on the catalyst calendar · ADRX registry changes
- Primary completion Apr 30, 2030Sponsor estimatePhase 2NCT06989359Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseADARx Pharmaceuticals, Inc. · IgANRecruitingADRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 28, 2030Sponsor estimatePhase 2NCT06990269Phase 2 Study of ADX-038 in Participants With Geographic AtrophyADARx Pharmaceuticals, Inc. · Geographic Atrophy Secondary to Age-related Macular DegenerationRecruitingADRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 6, 2026ActualPhase 1NCT06205628Safety, Tolerability, PK and PD of ADX-850 in Participants With HypertensionADARx Pharmaceuticals, Inc. · HypertensionActive, not recruitingADRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 22, 2027Sponsor estimatePhase 1NCT07081503Phase 1 Study of ADX-626 in Healthy ParticipantsADARx Pharmaceuticals, Inc. · Healthy Adult ParticipantsRecruitingADRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2027Sponsor estimatePhase 3NCT06960213STOP-HAE: A Phase 3 Study of ADX-324 in HAEADARx Pharmaceuticals, Inc. · Hereditary AngioedemaRecruitingADRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 10, 2028Sponsor estimatePhase 2NCT07522099Chinese Adults With Kidney DiseaseADARx Pharmaceuticals, Inc. · Immunoglobulin A Nephropathy (IgAN)RecruitingADRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2030Sponsor estimatePhase 3NCT07428499Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)ADARx Pharmaceuticals, Inc. · Hereditary Angioedema (HAE)RecruitingADRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2028Sponsor estimatePhase 1/Phase 2NCT05876312Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) PatientsADARx Pharmaceuticals, Inc. · Paroxysmal Nocturnal Hemoglobinuria (PNH)RecruitingADRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2027Sponsor estimatePhase 1/Phase 2NCT05691361Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema PatientsADARx Pharmaceuticals, Inc. · Hereditary AngioedemaActive, not recruitingADRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner